Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS01 in Locally Advanced or Metastatic Solid Tumors
NCT07461181Phase 2Active, not recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of CS01 in solid tumor (4 arms), sponsored by Ruijin Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events and Serious Adverse Events at 2 years and 2 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
CS01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07461181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07461181.